HOUSTON, TX, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, is pleased to announce the launch of Phase 1 of its proprietary virtual clinic. The virtual clinic will utilize artificial intelligence (AI) and Nexalin’s new Electronic Data Capture (EDC) platform and Patient Monitoring System (PMS). This AI ecosystem is designed to allow the entire clinical trial process—and ultimately the treatment experience—to be conducted virtually in the privacy of patients’ homes while providing physicians with real-time digital data related to the patient’s treatment experience. This innovative AI platform is being designed to manage Nexalin’s virtual clinic and clinical research capabilities, as well as streamline the patient experience for its Generation 3 Halo Device.
Recently, Nexalin announced its plan to transition its groundbreaking brain-stimulation technology from traditional mental health clinics into patients’ homes with the Gen-3 Halo headset. The Halo headset administers Nexalin’s 15mAmp deep frequency stimulation to the brain. The entire treatment process is non-invasive and undetectable to the patient. Clinical data supports the safety and efficacy of Nexalin’s advanced 15mAmp waveform for addressing mental health challenges, including depression, insomnia, Alzheimer’s disease, addiction, and other conditions. The Halo headset requires FDA clearance as a medical device, along with a prescription and monitoring by a physician. Halo is designed to be used in the privacy of a patient’s home, in an AI-based virtual setting while supervised by a licensed physician.
